MedTrace Logo

Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT01142856 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2012-05-03

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.

Conditions

Interventions

BIOLOGICAL

autologous mesenchymal stem cells

single intrathecal dose of 10x6 cells by lumbar puncture.

Sponsors & Collaborators

Principal Investigators

  • Anthony J. Windebank, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01142856 on ClinicalTrials.gov